FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Antimicrobial Drugs Panel Renewed

Federal Register notice: FDA renews its Antimicrobial Drugs Advisory Committee for an additional two years.

latest-news-card-1
Human Drugs

FDA Taps Murphy to Head Generic Drugs Office

FDA names CDER Office of Generic Drugs safety and clinical evaluation acting director Iilun Murphy as the next OGD director, replacing Sally Choe, who...

Human Drugs

FDA Approves Production at BMS CAR T Facility

FDA greenlights commercial production of CAR T cell therapy at a new Bristol Myers Squibb manufacturing site in Devens, MA.

latest-news-card-1
Human Drugs

Panel Backs RSV Monoclonal Antibody

FDAs Antimicrobial Drugs Advisory Committee votes unanimously that AstraZeneca and Sanofis nirsevimab has a favorable benefit-risk assessment for prev...

latest-news-card-1
Human Drugs

FibroGens Pamrevlumab Fails Phase 3

FibroGen says its pamrevlumab failed to meet the primary endpoint in treating Duchenne Muscular Dystrophy in a Phase 3 trial.

latest-news-card-1
Medical Devices

AdvaMed Recommendations for Patient Preference

AdvaMed says it agrees with FDA on questions to be added to a guidance on the submission of patient preference information, and also recommends change...

latest-news-card-1
Medical Devices

Teleflex Pacing Guidewire Cleared

FDA clears a Teleflex 510(k) for its Wattson Temporary Pacing Guidewire a bipolar temporary device designed specifically for use during transcatheter...

latest-news-card-1
Federal Register

ICH Guide on Good Clinical Practice

Federal Register notice: FDA makes available a draft guidance entitled E6(R3) Guideline for Good Clinical Practice.

latest-news-card-1
Federal Register

Braun EUA Revoked on Propofol-Lipuro

Federal Register notice: FDA revokes an emergency use authorization issued to B. Braun Melsungen AG for propofol-lipuro 1% injectable emulsion.

latest-news-card-1
Biologics

CBER Post-Covid Transition Information

CBER updates information for regulated entities on the return to normal operations with the end of the Covid-19 public health emergency.